Regeneron Pharmaceuticals, Inc. (BMV:REGN)

Market Cap	1.13T
Revenue (ttm)	268.05B
Net Income (ttm)	84.08B
Shares Out	n/a
EPS (ttm)	748.18
PE Ratio	13.38
Forward PE	13.66
Dividend	35.03 (0.33%)
Ex-Dividend Date	May 20, 2025

Volume	6,010
Average Volume	363
Open	10,677
Previous Close	10,200
Day's Range	10,677 - 10,677
52-Week Range	9,420 - 23,707
Beta	n/a
RSI	60.38
Earnings Date	Aug 1, 2025

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq...

• Industry: Pharmaceutical Preparations
• Founded: 1988
• Employees: 15,106
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: REGN

Financial Performance

In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.

Financial numbers in USD